Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912512 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL1000470 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL10896003 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL6798442 | 0.93 | LPAR1 (0.55) | PRKCAALDH1A1LPAR1LPAR3 | |
| SCHEMBL6798446 | 0.93 | LPAR1 (0.55) | PRKCAALDH1A1LPAR1LPAR3 | |
| SCHEMBL7411764 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL1008410 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL5493689 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL2732833 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL27795601 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398751-A1 | Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240325342-A1 | Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240325343-A1 | Methods of reducing symptoms of the ingestion of drugs such as cannabis or 5ht2 agonists via applications with 5ht1/2, CB1, GLP-1 allosteric modulators where the method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills. | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240325345-A1 | Methods of increasing effects of the ingestion of drugs such as cannabis or 5ht2 agonists via applications with 5ht1/2, CB1, opiate allosteric modulators as/in foods, beverages, vaporizer, smoking and supplement products/formulations. | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240325344-A1 | Methods of reducing symptoms of the ingestion of drugs such as cannabis or 5ht2 agonists via applications with 5ht1/2, CB1, GLP-1 allosteric modulators as/in foods, beverages, vaporizer, smoking and supplement products/formulations. | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240299341-A1 | Methods of treating or reducing symptoms of nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation via combination therapy with allosteric modulators and phenethylamines. | HELDRETH JR DAVID ALAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240269107-A1 | Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines. | HELDRETH JR DAVID ALAN (US) | 2024-08-15 | — | — | US | claimed |
| US-5837548-A | PRIMING CELLS FOR LIPID FORMATION, DETERMINING EXTENT OF LIPID BODY FORMATION, COMPARING WITH CONTROL AND ASSESSING INFLAMMOTORY ACTIVITY | BETH ISRAEL HOSPITAL (US) | 1998-11-17 | — | — | US | claimed |
| US-5686103-A | BINDING A PRODUCT TO THE MEMBRANE OF A MELANOCYTE BY MEANS OF A LIGAND-RECEPTOR BOND | PARFUMS CHRISTIAN DIOR (FR) | 1997-11-11 | — | — | US | claimed |
| US-5646185-A | Tumor treatment method | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-07-08 | — | — | US | claimed |
| WO-1997020212-A1 | TREATMENT OF INFLAMMATION BY INHIBITION OF LIPID BODY FORMATION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1997-06-05 | — | — | WO | claimed |
| WO-1995010273-A1 | USE OF PROTEIN KINASE C ACTIVATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR KILLING HYPOXIC TUMOR CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-20 | — | — | WO | claimed |
| EP-1908452-A1 | Skincare composition providing a healthy look | L'Oréal (FR) | 2008-04-09 | — | — | EP | disclosed |
| US-20080081057-A1 | COMPOSITION HAVING A HEALTHY APPEARANCE EFFECT | L'OREAL (FR) | 2008-04-03 | — | — | US | disclosed |
| EP-1039902-B1 | INHIBITORS OF GAP JUNCTION COMMUNICATION | SCRIPPS RESEARCH INST (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-1995010273-A1 | USE OF PROTEIN KINASE C ACTIVATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR KILLING HYPOXIC TUMOR CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5332575-A | Binding a product to a membrane | PARFUMS CHRISTIAN DIOR (FR) | 1994-07-26 | — | — | US | disclosed |
| US-H1168-H | Antiinflammatory agent for improving tissue and body organ recovering from bacteria infection consisting of lipid analoges in carrier | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1993-04-06 | — | — | US | disclosed |
| WO-1991007167-A1 | PROTEIN KINASE ACTIVATORS AS ENHANCERS OF MELANIN PRODUCTION | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |